Sen. John Boozman Sells Off Shares of IQVIA Holdings Inc. (NYSE:IQV)

Senator John Boozman (R-Arkansas) recently sold shares of IQVIA Holdings Inc. (NYSE:IQV). In a filing disclosed on November 15th, the Senator disclosed that they had sold between $1,001 and $15,000 in IQVIA stock on October 2nd.

Senator John Boozman also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Tortoise North American Pipeline Fund (NYSEARCA:TPYP) on 11/3/2025.
• Sold $1,001 – $15,000 in shares of Omnicom Group (NYSE:OMC) on 10/31/2025.
• Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 10/31/2025.
• Purchased $1,001 – $15,000 in shares of Costco Wholesale (NASDAQ:COST) on 10/9/2025.
• Sold $1,001 – $15,000 in shares of Sprott Lithium Miners ETF (NASDAQ:LITP) on 10/3/2025.
• Sold $1,001 – $15,000 in shares of iShares Silver Trust (NYSEARCA:SLV) on 10/3/2025.
• Sold $15,001 – $50,000 in shares of First Trust North American Energy Infrastructure Fund (NYSEARCA:EMLP) on 10/3/2025.
• Purchased $15,001 – $50,000 in shares of FT Energy Income Partners Enhanced Income ETF (NYSEARCA:EIPI) on 10/3/2025.
• Purchased $1,001 – $15,000 in shares of First Trust Global Tactical Commodity Strategy Fund (NASDAQ:FTGC) on 10/3/2025.
• Sold $1,001 – $15,000 in shares of Sprott Uranium Miners ETF (NYSEARCA:URNM) on 10/3/2025.

IQVIA Stock Performance

NYSE:IQV traded down $0.16 during mid-day trading on Wednesday, hitting $217.12. 162,750 shares of the company traded hands, compared to its average volume of 1,824,426. The stock’s fifty day moving average price is $203.84 and its 200-day moving average price is $179.79. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $228.12. The firm has a market cap of $36.98 billion, a price-to-earnings ratio of 29.77, a price-to-earnings-growth ratio of 2.43 and a beta of 1.34.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The company had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm’s revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the business earned $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Eric Sherbet sold 4,000 shares of IQVIA stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares in the company, valued at $5,955,627.60. This trade represents a 12.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.60% of the stock is owned by insiders.

Hedge Funds Weigh In On IQVIA

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Boston Partners purchased a new stake in IQVIA in the 3rd quarter worth about $676,698,000. Artisan Partners Limited Partnership purchased a new position in IQVIA during the 2nd quarter valued at $515,772,000. Norges Bank bought a new position in IQVIA in the 2nd quarter valued at $270,160,000. AQR Capital Management LLC lifted its position in shares of IQVIA by 130.2% during the second quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock worth $245,099,000 after purchasing an additional 879,701 shares during the last quarter. Finally, Pacer Advisors Inc. boosted its stake in shares of IQVIA by 5,036.1% during the first quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company’s stock valued at $153,681,000 after purchasing an additional 854,732 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on IQV. William Blair restated an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Baird R W upgraded IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 29th. Mizuho lifted their target price on IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. Weiss Ratings restated a “hold (c)” rating on shares of IQVIA in a report on Wednesday, October 8th. Finally, BMO Capital Markets began coverage on IQVIA in a report on Thursday, November 13th. They set an “outperform” rating and a $260.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $240.61.

About Senator Boozman

John Boozman (Republican Party) is a member of the U.S. Senate from Arkansas. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Boozman (Republican Party) ran for re-election to the U.S. Senate to represent Arkansas. He won in the general election on November 8, 2022. Boozman won re-election in 2016. He faced Democrat Conner Eldridge, Libertarian Frank Gilbert, and write-in candidate Jason Tate in the general election. Arkansas’ U.S. Senate race was rated as safely Republican in 2016. Boozman began his political career in the U.S. House. He won a special election in 2001 and served in that position until his election to the Senate in 2010. Prior to his political career, Boozman worked as an optometrist. As of a 2014 analysis of multiple outside rankings, Boozman is an average Republican member of Congress, meaning he will vote with the Republican Party on the majority of bills. Below is an abbreviated outline of Boozman’s academic, professional, and political career: 2011-Present: U.S. Senator from Arkansas 2001-2011: U.S. Representative from Arkansas 1977: Graduated from Southern College of Optometry

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.